LCH

LCH
Name	LCH
Field	Hematology; Oncology; Pathology

LCH LCH is a rare clonal disorder characterized by proliferation of pathological histiocytes derived from the monocyte–macrophage and dendritic cell lineages. It affects multiple organ systems, producing lesions in bone, skin, lung, liver, spleen, lymph nodes, and the central nervous system, and can present from infancy to adulthood. Management draws on protocols developed in pediatric oncology cooperative groups and adult hematology centers, integrating surgery, radiotherapy, systemic chemotherapy, targeted therapy, and supportive care.

Introduction

LCH was historically described in reports associated with pediatric case series and eponymous syndromes recognized in the 19th and 20th centuries by clinicians linked to institutions such as Great Ormond Street Hospital, St Bartholomew's Hospital, and research programs at Memorial Sloan Kettering Cancer Center. Contemporary classification stems from consensus meetings involving organizations like the World Health Organization and cooperative groups including the Children's Oncology Group and the International LCH Study Group. Molecular advances connecting somatic mutations in signaling pathways to clonal proliferation have aligned LCH research with work at centers such as the Dana-Farber Cancer Institute, Mayo Clinic, and MD Anderson Cancer Center.

Signs and symptoms

Clinical manifestations vary by organ involvement. Skeletal lesions commonly produce bone pain, swelling, or pathologic fracture often reported to orthopedic units at hospitals like Hospital for Special Surgery; skull, femur, pelvis, and ribs are frequent sites. Cutaneous involvement yields papules, rashes, or ulcerations seen by dermatology services at clinics such as Guy's and St Thomas' NHS Foundation Trust and Johns Hopkins Hospital. Pulmonary LCH presents with cough, dyspnea, spontaneous pneumothorax, and is encountered in pulmonary clinics including Royal Brompton Hospital and Cleveland Clinic; it is often associated with tobacco exposure. Endocrine dysfunction, notably diabetes insipidus from pituitary stalk lesions, leads to polyuria and polydipsia managed by endocrine units at institutions like Massachusetts General Hospital. Hepatosplenomegaly, lymphadenopathy, and cytopenias reflect multisystem dissemination observed in oncology practices at centers including Seattle Children's Hospital and Royal Children's Hospital, Melbourne. Neurodegenerative manifestations such as ataxia and cognitive decline have been described in long-term follow-up cohorts from research groups at Institut Gustave Roussy and Karolinska Institutet.

Causes and pathophysiology

LCH is driven by clonal expansion of pathological histiocytes bearing activating somatic mutations involving the MAPK/ERK pathway. Recurrent mutations such as BRAFV600E, MAP2K1, and ARAF have been identified in cohorts studied at Broad Institute, Institut Curie, and European Molecular Biology Laboratory. The BRAFV600E mutation links LCH biology to malignancies researched at Memorial Sloan Kettering Cancer Center and UCSF Medical Center, while MAP2K1 alterations connect to molecular oncology work at Cold Spring Harbor Laboratory. Lesional histiocytes express markers used in diagnostic pathology at laboratories like those at Mayo Clinic and Johns Hopkins Hospital including CD1a and Langerin (CD207), and ultrastructural Birbeck granules were originally characterized in electron microscopy studies at research centers such as Max Planck Institute and Institut Pasteur. The interplay between mutated histiocytes and the inflammatory microenvironment involving cytokines and T cells has been elucidated in translational studies from institutions such as Fred Hutchinson Cancer Center and Imperial College London.

Diagnosis

Diagnosis integrates clinical, radiologic, histopathologic, and molecular data. Imaging modalities include radiography, computed tomography, magnetic resonance imaging, and fluorodeoxyglucose PET/CT as applied in centers like Royal Marsden Hospital and Karolinska University Hospital. Definitive diagnosis requires tissue biopsy demonstrating CD1a+, Langerin+ lesional cells with supporting morphology reviewed by dermatopathology and hematopathology services at institutions such as Mayo Clinic and Mount Sinai Hospital. Molecular testing for BRAFV600E and MAP2K1 mutations is performed in molecular pathology laboratories at facilities including Broad Institute, Molecular Diagnostics Laboratory, Johns Hopkins, and Hospital Clínic de Barcelona. Endocrine evaluation, pulmonary function testing, and multisystem staging follow protocols developed by the International LCH Study Group and are implemented at tertiary referral centers like St Jude Children's Research Hospital and Peter MacCallum Cancer Centre.

Treatment and management

Therapeutic strategies are tailored by disease extent and organ risk classification. Localized bone lesions may be treated with curettage, limited radiotherapy, or intralesional steroids as practiced in orthopedic oncology services at Royal National Orthopaedic Hospital and Great Ormond Street Hospital. Multisystem disease often requires systemic chemotherapy regimens derived from pediatric trials coordinated by the Children's Oncology Group and international consortia, with agents including vinblastine, prednisone, and cytarabine used at pediatric oncology centers like Alder Hey Children's Hospital and Vanderbilt Children's Hospital. Targeted therapies such as BRAF inhibitors (e.g., vemurafenib) and MEK inhibitors (e.g., trametinib) have been applied in refractory cases in oncology programs at MD Anderson Cancer Center and Princess Margaret Cancer Centre. Supportive care addresses endocrinopathy with desmopressin at endocrine clinics like Royal Devon and Exeter Hospital, pulmonary rehabilitation at centers including Papworth Hospital, and psychosocial services provided by hospital networks such as Royal Children's Hospital, Melbourne.

Prognosis and epidemiology

Prognosis depends on age, extent of organ involvement, and risk-organ dysfunction; single-system bone disease generally carries a favorable outcome in cohorts from Children's Hospital of Philadelphia and Great Ormond Street Hospital, whereas multisystem disease with hepatic, splenic, or bone marrow involvement has higher morbidity and mortality as reported by the International LCH Study Group and registries at European Organisation for Research and Treatment of Cancer. Incidence estimates range from 1 to 9 per million per year in pediatric and adult populations studied in epidemiologic series from Scandinavian Childhood Cancer Registry, SEER Program, and national databases in France and Japan. Long-term sequelae include endocrine insufficiency, neurodegeneration, and secondary malignancies monitored in survivorship programs at institutions such as St Jude Children's Research Hospital and University College London Hospitals.

Category:Histiocytic disorders